Information Provided By:
Fly News Breaks for January 28, 2020
Jan 28, 2020 | 09:29 EDT
Baird analyst Jeff Johnson raised his price target on InMode to $55 from $45 following its approval for Evoke, the first hands-free non-invasive system by the FDA for facial remodeling. The analyst looks for continual improvement this year, with no change to forward estimates. Johnson reiterated his Outperform rating on InMode shares.
News For INMD From the Last 2 Days
There are no results for your query INMD